Regeneron ' s REGN-COV2 antibody cocktail: Prospective data from ongoing Phase 2/3 COVID-19 outpatient trial

Dear Investor, Please find attached a press release from our partner Regeneron:https://investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates For further information please also have a look at the attached Roche statement on REGN-COV2 data in non-hospitalised patients. Do not hesitate to contact us for any further questions. With best regards,
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news